17 Jun 2021
Discover the new Evolut™ PRO+ TAVI System
Sponsored by Medtronic
New data from Optimize PRO interim analysis
From a design built on a proven platform1, the Evolut™ PRO+ system provides the performance and outcomes you need to help patients live life to the fullest.
EXPECT MORE with Evolut™ PRO+:
- Hemodynamic performance for exceptional patient outcomes2
- Advanced Sealing for all valve sizes and across the broadest self-expanding annular range3
- Low Delivery Profile for access down to 5.0 mm vessels with the 23-29 mm valves
Discover Evolut™ PRO+ here
Leadership in Valve Design
Advanced Sealing across the Platform
The external tissue wrap on the Evolut™ PRO+ valve has shown excellent PVL performance within the recent Optimize PRO data4. With the addition of the wrap to the 34 mm valve, the advanced sealing technology is available across all the platform.
Watch the recorded session regarding the new Evolut™ PRO+ System from EuroPCR 2021
Watch the TNT session presented by D. Tchetche, T. Rudolph, A. Latib, D. Blackman regarding “The new Evolut PRO+ system: optimal procedural outcomes in all patients”
LEARNING OBJECTIVES
- To explore benefits of the new Evolut™ PRO+ system and its versatility to treat different patient anatomies
- To understand how the Cusp Overlap and commissural alignment techniques can help to ensure optimal outcomes and future coronary arterial access
- To discuss benefits of supra-annular, self-expanding platform in low-risk patients
Learn more about the Optimize PRO study - exceptional recent data on Evolut™ PRO+ and the Cusp Overlap Technique
Optimize PRO study investigators use the cusp overlap technique and a prespecified conduction disturbance, both of which have contributed to excellent clinical outcomes. Of the first 171 patients in the trial, 87.1% have been treated with the new Evolut™ PRO+ system.
- 0% moderate/severe PVL at discharge4
- 8.1 mm Hg gradient at discharge4
- 8.8% permanent pacemaker rate at 30 days4
- 1 day of median length of stay4
- 0 deaths and disabling strokes at 30 days4
- 0 pop-outs4
Discover here the recent interim data from Optimize PRO.
See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.
For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.
- Data on file (>20 clinical trials with over 20.000 patients enrolled)
- Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-expanding Valve in Low-Risk Patients N.Engl J Med. May 2, 2019:380(18) 1706-1715
- Broadest annulus range based on CT derived diameters for self-expanding valves.
- Grubb K, et al. An Optimized TAVR Care Pathway Using Evolut PRO and PRO+ Early Results from the Optimize PRO Study. Presented at SCAI 2021
Page published on June 2021.
With an unrestricted educational grant from Medtronic
